Drug Availability
HPS Pharmacies wish to give notice that Key Pharmaceuticals is experiencing a supply interruption for OsmoLax® as follows:
| Product |
Pack Size |
Expected Return Date |
| OsmoLax® |
510g |
Late March 2020 |
| OsmoLax® Relief |
595g |
Late March 2020 |
| OsmoLax® Relief |
7 x 17g |
Early April 2020* |
| OsmoLax® Relief Child |
298g |
Early April 2020 |
*Warehouses may still have limited stock in some states
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies
Drug Availability Update
HPS Pharmacies wish to advise that there is currently a supply interruption for famotidine tablets as follows:
Ausfam 20
Famotidine 20mg
ARTG 93788
Ausfam 40
Famotidine 40mg
ARTG 93789
Supplies of Ausfam 20mg are expected to return to normal in late March 2020. Supplies of Ausfam 40mg are expected to return to normal in late February 2020. Supplies of APO-Famotidine are long-term out of stock.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Arrow Pharma on 1300 927 769 or your pharmacist at HPS Pharmacies.
Drug Availability Update
Further to DrugAlert Volume 485, HPS Pharmacies wish to give notice that Seqirus is continuing to experience a supply interruption for BenPen™ as follows:
BenPen™ Vials
Benzylpenicillin (as sodium) 600mg
ARTG 10329
BenPen™ Vials
Benzylpenicillin (as sodium) 1.2g
ARTG 10326
Normal supplies of BenPen™ 600mg and BenPen™ 1.2g are expected to resume by end of February 2020. An internationally registered brand of benzylpenicillin 600mg and 1.2g vials has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please note that Section 19A alternatives are subject to a longer lead-time and different pricing as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Seqirus on (03) 9389 2000, or your pharmacist at HPS Pharmacies.
Drug Availability
HPS Pharmacies wish to give notice that Amdipharm Mercury Australia is experiencing a supply interruption for carbimazole as follows:
Neo-Mercazole® Tablets
Carbimazole 5mg
ARTG 194296
Availability is currently limited with normal supplies expected to resume by end of February 2020.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Amdipharm Mercury Australia on (02) 9431 6333 or your pharmacist at HPS Pharmacies.
Drug Availability
HPS Pharmacies wish to give notice that Orion Laboratories is experiencing a supply interruption for calcium gluconate gel as follows:
Calcium Gluconate Gel 50g
Calcium gluconate monohydrate 25mg/g
ARTG 11320
Normal supplies are expected to resume on 22nd May 2020.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Orion Laboratories on 1800 805 546 or your pharmacist at HPS Pharmacies.
Drug Availability
HPS Pharmacies wish to give notice that Alphapharm is experiencing a supply interruption for pindolol as follows:
Barbloc® 5 Tablets
Pindolol 5 mg
ARTG 17589
Normal supplies are expected to resume by the end of September 2020. An internationally registered brand of pindolol tablets has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please note that Section 19A alternatives are subject to a longer lead-time and different pricing as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Alphapharm on 1800 274 276 or your pharmacist at HPS Pharmacies.
Drug Availability Update
Further to DrugAlert Volume 448, HPS Pharmacies wish to give notice that all suppliers are continuing to experience a supply interruption for bleomycin 15,000 IU vials as follows:
An internationally registered brand of bleomycin vials has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. There are some important differences in the labelling and administration of this product. The internationally registered product is only to be used via the intramuscular, intravenous, and subcutaneous routes. While the strength of Australian products is expressed in international units (IU), the strength of the internationally registered brand is expressed in United States Pharmacopoeia units (USP units). The conversion factor is shown below:
Bleomycin 15 USP units = Bleomycin 15,000 IU
Please note that Section 19A alternatives are subject to a longer lead-time and different pricing as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Drug Availability Update
Further to DrugAlert Volume 562, HPS Pharmacies wish to give notice that Apotex is also experiencing a supply interruption for prazosin as follows:
| Product |
ARTG |
Expected Return Date |
| Minipress® 1mg |
10756 |
30th April 2020 |
| APO-Prazosin 1mg |
73858 |
Mid-April 2020 |
| Minipress® 2mg |
10757 |
28th February 2020 |
Minipress® 5mg is currently available, although a supply interruption is anticipated for this product between mid-March and mid-April 2020.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Drug Availability
HPS Pharmacies wish to give notice that there is a supply interruption for phenoxymethylpenicillin as follows:
| Product |
ARTG |
Current Status |
| Cilicaine VK 250mg capsules |
55675 |
Late February 2020 |
| Cilicaine VK 500mg capsules |
55676 |
Late February 2020 |
| Aspecillin VK 250mg tablets |
200136 |
Early April 2020 |
| Aspecillin VK 500mg tablets |
200137 |
Early April 2020 |
| LPV® 250mg capsules |
66510 |
Early April 2020 |
| LPV® 500mg capsules |
66511 |
End February 2020 |
An internationally registered brand of phenoxymethylpenicillin 250mg and 500mg tablets are available under Section 19A of the Therapeutic Goods Act 1989. Please note that Section 19A alternatives are subject to a longer lead time and different pricing as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Drug Availability
HPS Pharmacies wish to give notice that Pfizer is continuing to experience a supply interruption for dantrolene capsules and vials as follows:
| Product |
ARTG |
Expected Return Date |
| Dantrium® 25mg Capsules |
42975 |
End July 2020 |
| Dantrium® 50mg Capsules |
42976 |
End July 2020 |
| Dantrium® 20mg Vial |
14435 |
End June 2020 |
An internationally registered brand of dantrolene 25mg capsules and dantrolene 20mg injection vials are available under Section 19A of the Therapeutic Goods Act 1989. Please note that Section 19A alternatives are subject to a longer lead time and different pricing as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.
